Investigators are studying a new cancer immunotherapy to help patients with advanced pancreatic cancer -
medical investigators at Virginia G. Piper Cancer Center at Scottsdale Healthcare study a new immunotherapy cancer to see if it can successfully help patients with advanced pancreatic cancer.
The trial of Phase 2B of CRS-207 and GVAX Pancreas Vaccine is open at Virginia G. Piper Cancer Center at Scottsdale Healthcare Clinical Trials, a partnership with the Translational Genomics Research Institute (TGen), where cancer patients are treated with promising new drugs
participants in the study, called ECLIPSE (effectiveness of the combination Listeria / GVAX immunotherapy in pancreatic cancer Framework) will be randomized so that patients receive . single CRS-207 vaccine, or that the combination vaccine with the vaccine GVAX Pancreas and low dose cyclophosphamide. A third group of patients will receive standard chemotherapy.
"This is a very innovative approach using immunotherapy to treat pancreatic cancer," explained Dr. Erkut Borazanci, MD, MS, medical oncologist and development of drugs Scholar at Virginia G. Piper Cancer Center clinical trials at Scottsdale Healthcare and lead investigator of the study.
CRS-207 vaccine is a weakened form of the bacterium Listeria monocytogenes, which has been genetically modified to be safe for human consumption, while maintaining its ability to stimulate the immune system. Specifically, CRS-207 was designed to stimulate an immune response against the antigen mesothelin associated with a tumor, which is present at high levels on the cells of pancreatic cancer.
The GVAX vaccine is made, pancreatic cancer inactivated genetically modified cells that have been shown to stimulate the anticancer activity of the immune system. The vaccine is administered with a low dose of a drug against the common cancer called cyclophosphamide to enhance the effectiveness of the vaccine.
In a Phase 2A trial recently completed in 93 patients with advanced pancreatic cancer, survival was improved in patients who received the combined treatment of CRS-207, GVAX and cyclophosphamide (6 , 1 month), compared to 3.9 months for those who received only GVAX and cyclophosphamide. Immunotherapies were well tolerated, with no serious side effects associated with undesirable side processing.
Virginia G. Piper Cancer Center Clinical Trials is among the top 11 centers in the United States participating in the study. The drug was developed by Aduro BioTech, Inc., a clinical stage immunotherapy company located in Berkeley, California. A total of 240 patients should be treated at more than 20 clinical trial sites in North America.
"If this study is successful, we hope that this form of immunotherapy will become widely available across the country to treat patients with advanced pancreatic cancer," added Dr. Borazanci.
pancreatic cancer is difficult to treat and is the fourth leading cause of cancer deaths in the United States tumors can develop in the pancreas without any symptoms at first, which means that the disease is often an advanced stage when diagnosed, and survival remains low.
Virginia G. Piper cancer Center clinical trials is known worldwide for its expertise in the study of new treatments for pancreatic cancer .
people looking for information on eligibility to participate in clinical trials at cancer Center at Virginia G. Piper Scottsdale Healthcare may contact the coordinator of cancer care at 480-323-1339; toll free at 1-877-273-3713 or by email at clinicaltrials@shc.org. Additional information is available at http://www.clinicaltrials.gov (NCT004262).
EmoticonEmoticon